BOSTON SCIENTIFIC CORP
BSXNYSELatest results at a glance
Insights from the latest company results and reports
Quarterly Earnings Exceed Consensus
Reported EPS of $0.86 per share exceeded the same-quarter consensus estimate of $0.83 per share for the period ended 2026-06-30.
Revenue Growth Accelerates
Revenue for the quarter ended 2026-06-30 was $5.44bn, up 7.53% from $5.06bn in the same quarter of the prior year.
Interventional Cardiology Segment Leads
Interventional Cardiology Therapies revenue reached $586.0m, representing 10.8% of consolidated revenue and increasing 17.4% year over year.
Gross Margin Expansion
Gross margin for the quarter ended 2026-06-30 was 70.71%, wider than the 67.65% recorded for the quarter ended 2025-06-30.
Net Income Increases
Net income for the quarter ended 2026-06-30 was $905.0m, up 13.84% from $795.0m in the same quarter of the prior year.
Company research evidence
Checked financial measurements with the values, reporting periods and measurement basis shown together. This evidence is available independently of the AI report.
Loading evidence…
Deep Dive Research
Source-linked company research for BSX
Revenue segmentation
Loading segment disclosures…